Holzgerlingen, Germany, December 6, 2012 -- Curetis AG today announced the start
of a clinical trial of its Unyvero™ System and the corresponding LRT (lower respiratory
tract) application in the U.S. The company expects enrollment completion within the
next 12-15 months, followed by a 510(k) submission to the FDA in 2014.
The prospective, multicenter trial will include samples collected from more than 2,000
hospitalized patients suspected to have a lower respiratory tract infection and several
hundred retrospective samples with known microbiology culture results for rare patho-
gens. Samples will be processed by the Unyvero™ Lysator, transferred to the LRT
cartridge, and tested by the Unyvero™ Analyzer.
Primary endpoint of the study will be assay performance de? ned as clinical sensitivity
and speci? city compared to microbiology culture (today’s diagnostics standard of care)
and to a composite reference diagnosis that incorporates PCR and sequencing to
determine clinical truth whenever microbiology culture results are negative.
Trial sites include Northwestern University (Chicago, IL) and North Shore-LIJ Health
System (Lake Success, NY), among others. The Principal Investigator is Prof. Chris-
tine C. Ginocchio, Senior Medical Director and Chief, Division of Infectious Disease
Diagnostics, North Shore-LIJ Health System. Curetis has contracted Aptiv Solutions
as its CRO and Neil Mucci of GlobalBioclinical as project manager in the US.
“With shipment of instruments and cartridges and training of the ? rst sites completed,
we expect the ? rst three sites to be initiated during the next few weeks,” said Oliver
Schacht, CEO of Curetis. “Based on an intensive and engaged dialog with the FDA
and our regulatory affairs advisors over the past 24 months, we have designed a study
protocol to meet FDA requirements. We are very happy that we were able to effective-
ly establish a path forward for our highly multiplexed, PCR-based cartridge.”
“With current standard microbiology, it takes up to 72 hours to provide the clinician
with initial information on the types of organisms causing a life-threatening infection
and also the appropriate antibiotics that can be used as treatment,” said Christine Gi-
nocchio. “This can delay appropriate therapy and if a patient is not treated with an ap-
propriate antibiotic regimen from the beginning, this can result in increased morbidity
and mortality. We are therefore very much looking forward to test the Unyvero System.
Faster, accurate and reliable testing will be of tremendous clinical bene? t and greatly
improve the quality of patient care.”
The LRT application analyzes 39 DNA targets simultaneously from a single patient
sample. Results are available within about 4 hours. The pathogen panel has been
selected for clinical relevance based on current international clinical guidelines and
has been reviewed by clinical experts in Europe and the USA. Resistance genes were
chosen by frequency and clinical signi? cance. A similar product, the Unyvero™ P50
pneumonia cartridge is CE-marked and currently marketed in Europe and the Middle
Caution - Investigational Device, Limited by Federal (or US) Law to Investigational
Use. Not available for sale in the United States. Performance characteristics for this
device have not yet been established and the U.S. FDA has not yet cleared the de-
About the Unyvero™ System
The CE-marked Unyvero™ System is a versatile hardware platform for the detection
of a broad panel of bacteria and antibiotic resistances from a single sample in one
run. It processes a disposable cartridge providing the necessary reagents to complete
the analysis from sample to result.
The platform enables the DNA-based testing of all clinically relevant samples in a fully
automated, unsupervised analysis process requiring only few, quick manual prepara-
tion steps. The analysis thus can be performed with minimal operator time and without
the need of skilled staff or special infrastructure.
Thereby, clinically relevant information is available within about four hours to support
an informed therapy decision as early as possible.
The ? rst CE-marked Unyvero™ Cartridge, Unyvero™ P50, focuses on pneumonia
testing and simultaneously analyses 39 DNA targets. The second Unyvero™ applica-
tion for implant & tissue infections is already in product development. Cartridges for
additional indications, such as blood stream infections and tuberculosis, are in prepa-
About Curetis AG
Founded in 2007, Curetis AG is a molecular diagnostics company which focuses on
the development and commercialization of reliable, fast and cost-effective products
for diagnosing severe infectious diseases. The diagnostic solutions of Curetis AG will
enable rapid multiparameter pathogen and antibiotic resistance detection in only a few
hours, a process that today can take up to days or even weeks with other techniques.
To date, Curetis has raised total funds of over € 36.6 million (~ USD 50 million). The
company is based in Holzgerlingen near Stuttgart, Germany. Curetis has signed col-
laboration agreements with Heraeus Medical, Sano? Pasteur and Cempra Inc. as well
as several international distribution agreements.
Tel. +49 (7031) 49195-10
Fax +49 (7031) 49195-19
71088 Holzgerlingen, Germany
Tel. +49 (0) 7031 49195-10
Dr. Ludger Wess / Ines-Regina Buth
Tel. +49 40 88 16 59 64
Tel. +49 30 23 63 27 68